- About the Study
- The purpose of this study is to evaluate the safety and efficacy of an oral investigational drug when given to patients with NSS. The results of this study will provide more information about whether the investigational drug could one day help patients who are experiencing the negative symptoms of schizophrenia.
- What does the study involve?
- Participants will be randomly assigned to receive the investigational drug or placebo. An investigational drug is a drug that has not been approved as a treatment by any health authority. Study participants will take their study drug (investigational or placebo) two times a day for approximately 15 weeks. Study participation includes seven visits to the study center and six phone calls from the study staff. At study center visits, the study doctor and study staff will evaluate the health of each participant and their response to the study drug.
- Who can participate?
- You must be between 18 and 60 years of age and have had onset of symptoms of schizophrenia for at least one year. You must also be experiencing negative symptoms of schizophrenia for at least six months, and have a reliable study partner who can answer questions about them.
- Where is the study taking place?
- The study is being conducted at our Hollywood office.
- Is compensation provided?
- Yes, you will be compensated for your participation. Travel reimbursement and meals are not provided.